Amphastar rises after FDA approves new over-the-counter overdose spray
16/06/2026 14:15
BUZZ-Amphastar rises after FDA approves new over-the-counter overdose spray ** Shares of drugmaker Amphastar Pharmaceuticals AMPH.O rise 2% to $20 premarket
** FDA says it approved Rextovy, a 4mg naloxone nasal spray for opioid overdose, for sale without prescription
** AMPH's naloxone reverses the effects of opioid overdose, as drugs like fentanyl can slow or stop breathing
** FDA says product to be sold via pharmacies, convenience stores and online, increasing access
** Says approval adds competition in OTC naloxone market, helping widen availability and lower costs
** FDA says spray is safe even if opioid involvement unclear and urges users to seek emergency help after use
** As of last close, stock was down ~26% YTD
(Reporting by Sahil Pandey in Bengaluru)
Recent news on Amphastar Pharmaceuticals,
See all newsU.S. STOCKS ON THE MOVE-RBB Bancorp, Roblox, Open Lending
U.S. STOCKS ON THE MOVE-Amkor Technology, Dynatrace, Corvex
Amphastar rises after FDA approves new over-the-counter overdose spray
Brief: FDA Broadens Access To Over-The-Counter Naloxone Nasal Spray For Opioid Overdose
U.S. RESEARCH ROUNDUP-Airbnb, HII, Tesla